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Abstract
Background: The introduction of specific BCR-ABL inhibitors in chronic myelogenous leukemia therapy has entirely mutated
the prognosis of this hematologic cancer from being a fatal disorder to becoming a chronic disease. Due to the probable
long lasting treatment with tyrosine-kinase inhibitors (TKIs), the knowledge of their effects on normal cells is of pivotal
importance.
Design and Methods: We investigated the effects of dasatinib treatment on human bone marrow-derived mesenchymal
stromal cells (MSCs).
Results: Our findings demonstrate, for the first time, that dasatinib induces MSCs adipocytic differentiation. Particularly,
when the TKI is added to the medium inducing osteogenic differentiation, a high MSCs percentage acquires adipocytic
morphology and overexpresses adipocytic specific genes, including PPARc, CEBPa, LPL and SREBP1c. Dasatinib also inhibits
the activity of alkaline phosphatase, an osteogenic marker, and remarkably reduces matrix mineralization. The increase of
PPARc is also confirmed at protein level. The component of osteogenic medium required for dasatinib-induced
adipogenesis is dexamethasone. Intriguingly, the increase of adipocytic markers is also observed in MSCs treated with
dasatinib alone. The TKI effect is phenotype-specific, since fibroblasts do not undergo adipocytic differentiation or PPARc
increase.
Conclusions: Our data demonstrate that dasatinib treatment affects bone marrow MSCs commitment and suggest that TKIs
therapy might modify normal phenotypes with potential significant negative consequences.
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Introduction
The treatment of chronic myelogenous leukemia (CML) with
specific tyrosine kinase inhibitors (TKIs) has entirely mutated the
prognosis of this hematologic cancer from being a fatal disorder to
becoming a chronic disease, in which the patients might be on
treatment for decades [1–4]. Three major TKIs are employed in
CML therapy, namely imatinib mesylate (ST-571, GleevecH,
Novartis), nilotinib (AMN107, TasignaH, Novartis), and dasatinib
(BMS354825, SprycelH, Bristol Myers Squibb).
Imatinib mesylate was introduced in therapy in 1998 as a potent
and specific inhibitor of BCR-ABL protein, the recombinant kinase
responsible for CML development [5]. The molecule is also able to
inhibitthe tyrosinekinase activityofABL, c-Kit,c-FMS,Sykand the
receptor of platelet-derived growth factor (PDGFR) [3]. Imatinib is
highly effective in chronic phase CML [6]. The TKI induces a high
percentage of complete hematologic response, and a significant
progression-free survival rate without accelerated or blast crisis [7,8].
However, a small number of patients develop a suboptimal
response or resistance to imatinib mesylate [9]. In order to
overcome this resistance, second-generation BCR-ABL inhibitors
have been developed, including nilotinib and dasatinib. Nilotinib,
although more potent than imatinib in inhibiting BCR-ABL
activity, displays a selectivity for the same target kinases as imatinib
[10,11]. No significant activity is shown against other kinases
including Src, FLT3, VEGFR, EGFR, InsR, RET, MET or IGFR
[12]. Dasatinib is a powerful, second-generation, multitarget kinase
inhibitorofBCR-ABL.The compound wasdevelopedinitiallyasan
inhibitor of Src family kinases such as Fyn, Yes, Src, and Lyk, but it
also inhibits BCR-ABL, EphA2, PDGFR, and c-Kit [13,14].
Additionally, it binds to and inhibits other tyrosine and serine/
threonine kinases, such as mitogen-activated protein kinases
(MAPK) and tyrosine kinase discoidin domain receptor [13,14].
Patients affected by CML and treated with imatinib have been
reported to show alteration of bone metabolism. A number of
studies suggested initially that the TKI might have a positive effect
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observed a 4% increase in spinal bone mass density in nine
imatinib-treated CML patients, not paying, however, attention to
the subjects body weight and fat mass increase [15] that are factors
known to positively influence bone mass [18].
Very recently, the same group has demonstrated that in healthy
rodents imatinib treatment does not increase bone mass [19].
They have also suggested that the previously reported improve-
ments in bone density of patients receiving imatinib may not be
directly dependent on the drug [19]. Indeed, either a decrease of
serum osteocalcin or an osteoblast number reduction have been
consistently reported, being coherent with imatinib’s inhibition of
osteoblast proliferation and survival in vitro [20]. These findings
also agree with additional data from human studies reporting a
lowering of osteogenesis serum markers after long-term imatinib
therapy [15,17,21,22]. In summary, the majority of data, although
not being conclusive, suggest that imatinib impairs osteoblast
proliferation and, after a prolonged therapy, negatively affect bone
turn-over.
Bone marrow is a complex cellular array containing stem cells
of both hematopoietic and nonhematopoietic lineages. Hemato-
poietic stem cells are capable of self-renewal and can develop into
any kind of blood cell, while the nonhematopoietic elements,
called mesenchymal stem cells or, better, mesenchymal stromal
cells (MSCs) [23], create a supportive bone marrow niche for the
hematopoietic stem cells [24,25]. In addition, MSCs can
differentiate into a variety of cell phenotypes including osteoblasts,
adipocytes and chondrocytes [26–29]. The two types of bone
marrow stem cells interact and dialogue each other and a series of
studies has suggested the importance of cytokine production and
reciprocal contact for the growth and survival of both bone
marrow cellular components [28]. Thus, MSCs have a pivotal role
in bone remodeling and play a central function in haematopoiesis.
Here we investigated the effect of dasatinib on human MSCs
differentiation. The interest in this study stems from the MSCs
multiple roles and the probable prolonged course of dasatinib
treatment. Moreover, the multitarget kinase inhibitor was selected
since it has been approved for use in CML patients and is under
evaluation for the treatment of numerous other cancers.
Materials and Methods
Ethics statements
K562 cell line strain employed in this study was kindly given by
Prof. P. Auberger, INSERM U895 (C3M), Faculte ´ de Medecine,
Nice, FRANCE. MSCs were obtained employing heparinized
human bone marrow from healthy volunteers. The study was
approved by the Medical Ethics Committee of the Second
University of Naples and was performed in accordance with the
Declaration of Helsinki. Written informed consent was obtained
from all subjects prior to participation in the study.
Reagents
Dasatinib and bosutinib were furnished by LC Laboratories
(Woburn, MA, USA). Tissue culture biochemicals were from
Invitrogen (Grand Island, NY, USA), and plasticware was
obtained from BD Falcon (Franklin Lakes, NJ, USA). All the
chemicals were obtained, unless otherwise stated, from Sigma (St
Louis, MO, USA), and were of the highest grade commercially
available. The nuclear and cytoplasmic extraction kit (Ne-Per) was
furnished by Pierce Biotechnology (Rockford, IL, USA). Mono-
clonal antibodies against PPARc (E8, sc-7273), phospho-Erk1/2
(K23, sc-7383), phosphotyrosine (PY20, sc-508), and polyclonal
antisera against Erk1/2 (K23, sc-94), HDAC1 (H51m, sc-7872),
cofillin (FL-166 sc-33779) were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Monoclonal antibodies against p27
Kip1
were from Transduction Laboratories (Lexington, UK). Polyclonal
antibodies against b-actin were from Sigma.
Preparation and characterization of human bone
marrow-derived mesenchymal stromal cells
MSCs were obtained employing heparinized human bone
marrow from healthy volunteers. MSCs cultures were initiated as
previously described [30]. Briefly, the bone marrow sample was
diluted 1:5 with Opti-MEM containing 10% fetal calf serum
(FCS), penicillin 100 units/ml, streptomycin 100 mg/ml and
sodium ascorbate 50 mg/ml (growth medium) and incubated at
37uC in a 5% CO2 humidified atmosphere. After 48 h
incubation, the medium was collected and centrifuged at
800xg. The pellet was discarded, while the corresponding
supernatant was added again to the dish. In three-four days,
several foci of adherent spindle-like cells appeared and grew until
subconfluence in the following two weeks. Afterwards, cells were
trypsinized, and their phenotype was confirmed by flow
cytometry using a wide panel of labeled monoclonal antibodies.
Precisely, MSCs expressed specific surface markers, such as
CD13 (clone L138, BD Biosciences, Milan, Italy), CD29 (Anti-
Integrin beta 1 antibody, clone EP1041Y-Carboxyterminal end,
Abcam, Cambridge, USA), CD44 (Anti-CD44 antibody, clone
F10-44-2, Abcam), CD105 (clone SN6; Serotec, Kidlington,
Oxford, UK), and were negative for hematopoietic cell markers
CD14 (clone MFP9, BD Biosciences), CD34 (clone 581, BD
Biosciences), and CD45 (clone HI30, BD Biosciences) [30].
Analysis of cell populations was done by means of direct
immunofluorescence with a FACSCalibur flow cytometer (BD
Biosciences) and data were calculated using CellQuest software
(BD Biosciences). Figure S1 reports an example of MCSs FACS
analysis. Only early cultures, between the second and fourth
passage, were used in our experiments.
Induction of osteoblastic differentiation and staining
methods
The effects of the tested TKI on osteogenic differentiation were
evaluated analyzing the expression of two specific markers, namely
alkaline phosphatase (AP) activity and mineralization of the
extracellular matrix. Usually, cells were seeded at a density of 10
4
cells/cm
2 in 6-well plates. The day after, the medium was replaced
by fresh medium supplemented with or without the molecules
under investigation. After 7 days, AP specific activity was
evaluated. Once removed the medium, wells were rinsed with
20 mM Tris/HCl, pH 7.4, 0.5 M NaCl (TBS) and the cells lysed
by a specific buffer (20 mM Tris/HCl, pH 7.4, 0.5 mM NaCl,
0.25% Triton X-100, 0.5 mM phenylmethylsulfonyl fluoride,
0.5 mM DTT). After 30 min in ice, the cell lysates were
centrifuged at 13,000g for 5 min, and the supernatants assayed
for AP activity. AP activity was determined by measuring the
release of para-nitrophenol from disodium para-nitrophenyl
phosphate. The reaction mixture contained 10 mM disodium
para-nitrophenyl phosphate, 0.5 mM MgCl2, 0.1 M diethanol-
amine phosphate buffer pH 10.5, and 10–30 mg of cell lysate in a
final volume of 0.5 ml. After 30 min at 37uC, the reaction was
stopped by adding 0.5 ml of 0.5 M NaOH. Para-nitrophenol levels
were measured spectrophotometrically at a wavelength of 405 nm.
One unit was defined as the amount of enzyme that hydrolyzes 1
nmol of para-nitrophenyl phosphate/min under the specified
conditions.
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4
cells/cm
2 in 6-well plates and, after a day, incubated in a medium
supplemented with or without the molecules under investigation.
After one week, the osteogenic medium (OM) was added (50 mg/
ml L-ascorbic acid, 10 mM b-glycerophosphate and 100 nM
dexamethasone) and the cells were cultured as specified in the
Results Section.
Both the o-cresolphthalein complexone method and Alizarin Red
Staining were employed to evaluate the mineralization of the
extracellular matrix. For the o-cresolphthalein complexone method,
the cells were washed with PBS, scraped from the plate, transferred
into a 1.5-ml microcentrifuge tube and subjected to the decalcifi-
cationwith0.6NHClfor24 hatroomtemperature.Theslurrywas
then centrifuged at 12,000g for 10 min and 500 mlo ft h e
supernatant were transferred into a new tube: the calcium released
in the supernatants was determined colorimetrically at 540 nm. For
Alizarin Red Staining method, cells were washed with PBS and
fixed in 10% (v/v) formaldehyde for 15 min at room temperature.
The monolayers were washed with distilled water and added with
1 ml of 40 mM Alizarin RedS (pH 4.1). After 20 min incubationat
room temperature with gentle shaking, the unincorporated dye was
removed and the cells were washed with distilled water prior to
proceed to the quantification. For quantification of staining, 800 ml
10% acetic acid was added to each well. The monolayers were then
scraped from and transferred into a 1.5-ml microcentrifuge tube.
After vortexing for 30 s, the slurry was overlaid with 500 ml mineral
oil, heated to 85 uC for 10 min, transferred to ice for 5 min, and
centrifuged at 20,000g for 15 min. Then, 500 ml of the supernatant
was removed to a new tube and 200 ml of 10% ammonium
hydroxide was added to neutralize the acid. Aliquots (150 ml) of the
supernatant were read in triplicate at 405 nm.
Induction of adipocytic differentiation and Sudan red
staining
Cells were seeded at 10
4 cells/cm
2 and cultured in the standard
growth medium. At 90–100% cell confluence, the medium was
supplemented with the adipogenic components (1 mM dexameth-
asone, 0.45 mM 3-isobutyl-1-methylxanthine, 6 mM insulin), and
MSCs were cultured as described in Results Section. Adipocytic
differentiation was evaluated by using Sudan red staining. Briefly,
cells were fixed in 0.5% glutaraldehyde for 15 min at room
temperature and rinsed twice in PBS. Filtered Sudan red
supersaturated solution in 60% isopropanol was added to the
MSCs: after 15 min staining, the cells were washed once with 60%
isopropanol and twice with PBS. Adipocytes, containing lipid
droplets, stained red.
Semi-quantitative reverse transcriptase-PCR (RT-PCR)
assay
Reverse-transcriptase PCR was mainly performed as reported
[31]. The sequences of the primers employed for the different
transcripts analyzed (PPARc, CEBPa, LPL, SREBP1c and
GAPDH) are available on request. After PCR reaction, the
products were separated by electrophoresis on 2% (w/v) agarose
gel and visualized by ethidium bromide staining. Gels were scanned
with FLA-5000 imaging system (Fujifilm, Tokyo, Japan) and Image
Reader software (RaytestH, Straubenhardt, Germany) [31].
Quantitative RT- PCR
Messenger RNA expression of PPARc was quantified by
quantitative RT-PCR using SYBRH Green dye (SYBRH Green
PCR Master Mix, Applied Biosystems, Foster City, CA, USA) and
sequence-specific primers [31]. Total RNA from control and
treated cells was isolated using Tripure method (Roche Diagnostics,
Monza, Italy) [31]. Reverse transcription was performed using 1 mg
total RNA and the reverse transcriptionsystem (Promega, Madison,
WI, USA). The amplification was performed in an ABI PRISMH
7900 Sequence Detection System (Applied Biosystems, Monza,
Italy) with 40 cycles of a two-step PCR (95uC for 15 sec and 60uC
for 60 sec) after an initial activation step (95uC for 10 min). Melting
curves from 60uCt o9 9 uC were assessed to evaluate specificity.
Serial dilutions of purified amplicons served to generate standard
melting curves. Relative quantification was calculated by normal-
izing the test crossing thresholds (Ct) with the b-actin amplified
control Ct. The sequences of PPARc and b-actin primers employed
in the quantitative RT- PCR are available on request.
Cellular Fractionation and immunoblotting
Total cell extracts were prepared as reported [31,32]. Nuclear
and cytosol extracts were prepared using Ne-Per reagent,
following manufacturer’s instructions (Pierce). Extracts obtained
by this method were preliminary tested for cross-contamination
using antibodies against HDAC1 protein (as nuclear markers) and
against cofillin (as cytosolic proteins). Immunoblotting analyses
were carried out essentially as reported [31,32].
Results
1. Effect of dasatinib on the differentiation of MSC
In order to investigate the activity of dasatinib on the
mineralization process, we tested the effect of the molecule on
osteoblastic differentiation of bone-marrow human MSCs. To this
aim, MSCs, plated at high density, were treated with dasatinib for
7 days. Afterwards, the cells were cultured in OM supplemented
with the TKI. The dasatinib concentration employed (25 nM) was
chosen on the basis of the expected plasma TKI level of CML-
treated patients and the amount usually employed in studies with
other cellular models. Surprisingly, after 3 weeks, we evidenced
that the treatment not only negatively affected mineralization but
also it induced morphological changes typical of the adipocytic
differentiation (Figure 1A). In order to confirm the observation,
we incubated MSCs with two different amounts of the TKI. As
reported, in Figure 1B, adipogenesis was particularly evident
after incubation with 50 nM dasatinib.
The effect of TKI treatment was also evaluated in terms of both
AP activity and levels of calcium incorporated in the extracellular
matrix. Results showed that dasatinib significantly decreased the
AP activity (Figure 2A) and, consequently, given the pivotal role
of this enzyme in osteogenesis, inhibited the mineralization process
(Figure 2B,2C).
The adipocytic differentiation of dasatinib-treated MSC was
also confirmed by Sudan red staining, a method that evidences
intracellular lipid vacuole accumulation (Figure 3A).
In order to clarify which of the components of the OM could be
necessary for inducing adipogenesis, we tested them separately, in
the presence of the TKI. As reported in Figure 3 (panels B–D),
only dasatinib plus dexamethasone was able of inducing adipocytic
differentiation that did not occur following the treatment with b-
glycerophosphate plus the TKI or dexamethasone alone (not
shown). Thus, the steroid was the molecule of OM required for the
adipogenic effect of dasatinib.
2. Dasatinib activates the expression of biochemical
markers of adipogenesis in the presence of
dexamethasone
The up-regulation of the transcription factor PPARc (Peroxi-
some Proliferator-Activated Receptor c is a key feature of
Dasatinib and Mesenchymal Stromal Cells
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treatment of MSCs with 25 nM dasatinib followed, after one week,
by the addition of 100 nM dexamethasone was able to induce the
expression of the transcription factor. After 30 days, the samples
were collected and the content of PPARc was evaluated by semi-
quantitative PCR.
As shown in Figure 4A, dexamethasone alone faintly increased
the expression of the transcription factor, while the addition of
dasatinib to dexamethasone strongly up-regulated PPARc expres-
sion. The effect of the compounds on PPARc transcript level was
evaluated by quantitative PCR. As reported in Figure 4B,
dexamethasone alone increased PPARc expression of about 2.5
folds, while PPARc mRNA was strongly enhanced by dasatinib
plus dexamethasone (about 6-folds). Intriguingly, dasatinib alone
also up-regulated PPARc mRNA.
In subsequent experiments, we employed another second line
BCR-ABL inhibitor, namely bosutinib. This TKI was selected
since it is a Src/ABL kinase inhibitor (like dasatinib) with target
kinases largely superimposable to those of dasatinib. The
employed bosutinib concentration (100 nM) was chosen on the
basis of recent pharmacokinetics data [35].
We investigated the effect of dexamethasone alone, or added
with 25 nM dasatinib or 100 nM bosutinib. In these experiments,
the molecules (i.e dexamethasone and the two TKIs) were added
one day after MSCs plating. We also tested the activity of two
different concentrations of dexamethasone and the effect of
dasatinib alone. After 10 days treatment, total mRNA was
recovered and the content of PPARc CEBPa (CCAAT/
enhancer-binding protein alpha), LPL (Lipoprotein Lipase) and
SREBP1c (Sterol Regulatory Element-Binding Protein 1c) tran-
script was evaluated by RT-PCR. CEBPa is a nuclear factor
expressed concurrently to PPARc during the adipocytic differen-
tiation [36], while LPL and SREBP1c genes are key targets of active
PPARc[37,38].
As reported in Figure 5A, only dasatinib/dexamethasone
increased the expression of PPARc over the activity of dexameth-
asone alone. Dasatinib plus dexamethasone was also able to clearly
up-regulate the level of LPL transcript, thus confirming that the
newly formed PPARc was functionally active. The accumulation
of CEBPa and SREBP1c transcripts was also evident. In this
experiment, K562 cell line cDNA was employed as positive
control for SREBP1c transcript [39].
In order to clarify the effect of dasatinib alone (i.e without the
addition of dexamethasone), MSCs were cultured for 20 days in
the presence of dasatinib and bosutinib alone. Then, the levels of
PPARc, CEBPa and LPL transcription were evaluated by RT-
PCR. In this experiment, the number of PCR cycles was
increased (from 30 to 35 cycles) to identify low amounts of
transcripts. As shown in Figure 5B, dasatinib induced the
expression of the three genes investigated, while bosutinib did
show any effect. Also in this case, the levels of the transcripts were
remarkably increased by the addition of dexamethasone to
dasatinib (Figure 5B).
3. Dasatinib induces a strong increase of nuclear PPARc
protein in MSCs
All together the reported experiments demonstrated that the
adipogenic effect of dasatinib on MSCs was observed both at
morphological and mRNA level. However, in order to definitely
confirm our findings, we investigated PPARc accumulation also at
protein level.
As reported in Figure 6A, only dasatinib/dexamethasone
increased significantly the level of PPARc protein. A small
increase was also observed with the addition of dexamethasone
by itself, but not in the sample treated with bosutinib plus
dexamethasone versus dexamethasone alone.
It was also evident that dasatinib plus dexamethasone increased
significantly p27
Kip1, an inhibitor of cyclin-dependent kinases,
whose accumulation is both linked to the arrest of cells in G1
phase and, frequently, to the induction of differentiation.
Subsequently, we compared the effect of dasatinib alone with
the activity of adipogenic medium and OM on MSCs. In the
experiment, that lasted 25 days, we investigated the effect on
PPARcand p27
Kip1 levels. As reported in Figure 6B, the
adipogenic medium caused a clear increase of PPARc and
dasatinib by itself induced a small increase of the transcription
factor. Conversely, in both untreated and OM treated MSCs no
accumulation of PPARc was observed. The adipogenic medium
also caused a strong up-regulation of p27
Kip1, similarly to the effect
shown in Figure 6A by dasatinib plus dexamethasone.
In Figure 6C, we report the effect of dasatinib and bosutinib
alone after a period of incubation of 40 days. In this experiment,
primary cultures of human skin fibroblasts (a different mesenchy-
mal-derived cell phenotype) were also employed. Both the nuclear
and the cytosolic compartments were analyzed in order to
investigate PPARc localization. Dasatinib alone significantly
increased the level of the nuclear transcription factor in MSCs.
A slight increase was also observed in bosutinib treated MSCs.
Intriguingly, PPARc was localized exclusively at nuclear level,
indirectly confirming its activity. The level of PPARc did not
change in human fibroblasts before and after the treatment with
dasatinib and bosutinib, thus indicating that MSCs are specific
Figure 1. Effect of dasatinib on MSCs phenotype. Panel a) MSCs
were seeded at a density of 10
4 cells/cm
2. After one day, 25 nM
dasatinib (Das) was added. After one week, the osteogenic medium
replaced the growth medium. The osteogenic medium containing the
TKI was changed every 3 days. Finally, after additional 3 weeks, the
images of MSCs were captured as described in Materials and Methods.
Panel b) The experiments were performed exactly as reported in panel
a, except that the dasatinib was employed at 25 and 50 nM. The figure
is representative of 3 independent experiments.
doi:10.1371/journal.pone.0028555.g001
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of p27
Kip1 was observed in the cytosol of dasatinib-treated MSCs.
4. Dasatinib inhibits the activity of MAPK pathway in
MSCs
It has been previously reported that the treatment with the OM
increased in MSCs, at specific time interval, the activity of the
MAPK pathway [40]. Accordingly, MAPK inhibitors reduced the
osteogenic differentiation and induced adipogenesis [40]. Finally,
the treatment with the adipogenic medium significantly reduced
the activity of basal MAPK activity [40]. These findings suggest
that human MSCs osteogenesis is associated to activation of
MAPK pathway while down-regulation of Erk1/2 activation
might lead to MSCs adipogenesis [40,41]. Since dasatinib is a
strong inhibitor of several intracellular pathways including MAPK
[14], we hypothesized that its adipogenic activity might in part be
attributable to an effect on the signal transduction. Thus, we
evaluated the activity of the TKI on Erk1/2 phosphorylation. As
shown in Figure 6D, the molecule significantly reduced the
degree of MAPK pathway activity (days 7 and 9) and prevented
its activation by the OM (day 11). These findings suggest that the
down-regulation of MAPK pathway might be involved in the
effect of dasatinib on MSCs. The activity of dasatinib as tyrosine
kinase inhibitor in this experiment was confirmed by re-analyzing
the filter employed in Figure 6D with antibodies against
phosphotyrosine. A clear decrease of tyrosine phosphorylation
pattern was observed in MSCs treated with molecule (Figure 6E).
Discussion
In this study, we report for the first time that dasatinib, at
concentrations equivalent to those reached in serum during CML
treatment, induces the adipocytic differentiation of MSCs. The
heretofore unreported effect is endowed with significant clinical
relevance, being now the therapy of CML with TKIs a long-
lasting treatment. Importantly, dasatinib is also under evaluation
for the therapy of several solid cancers, including the carcinoma of
pancreas, prostate, breast, ovary and colon, as well as non-small
cell lung carcinoma [42–55].
The dasatinib-dependent MSCs adipocytic differentiation is
characterized by an initial accumulation of small lipid droplets that
fused in part, becoming larger cytosolic vacuoles. The positivity to
Sudan Red staining confirmed their lipidic content. We also
demonstrated that dasatinib-dependent adipogenesis requires
Figure 2. Characterization of dasatinib effect on MSCs osteogenesis. Panel a) MSCs cells were treated for one week with 25 nM or 50 nM
dasatinib (Das). Then, the activity of alkaline phosphatase was evaluated as described in Materials and Methods and expressed as percentage of
control. Panel b) MSCs cells were treated with 25 nM or 50 nM dasatinib (Das) following the scheme reported in Figure 1. At the end of the
treatment, the calcium content was evaluated by and o-cresophtalein complexone method, and expressed as percentage of control. Panel c) MSCs
cells were treated with 25 nM or 50 nM dasatinib (Das) following the scheme reported in Figure 1. At the end of the treatment, the calcium content
was evaluated by alizarin red staining and expressed as percentage of control. Each panel is representative of 5 independent experiments.
doi:10.1371/journal.pone.0028555.g002
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affect MSCs phenotype.
The effect of dasatinib on MSCs was confirmed by a large series
of molecular evidence. The TKI plus the corticosteroid strongly
induced the nuclear accumulation of PPARc, a transcription
factor that not only is critical for adipogenesis, but also represents a
specific marker of fat cell differentiation. Up-regulated PPARc
protein was fully active, since its increase stimulated the expression
of LPL and CREBP1c genes, two of its specific targets [33–37]. The
dasatinib-dependent MSCs adipogenesis was further confirmed by
the accumulation of CEBPa transcript, an independent marker of
adipocytic differentiation.
While the observation that dasatinib plus dexamethasone
induces adipogenesis is sustained by several morphological and
molecular data, the effects of dasatinib alone on MSCs phenotype
seem more complex to characterize. Several data (Figures 4B,
5B and 6B) suggest that the TKI induces PPARc up-regulation,
although at a much minor extent than when it was associated to
dexamethasone. However, under specific RT-PCR conditions (i.e.
a lower number of cycles), the effect of the TKI on PPARc level
was not evident (Figure 5A). The difference might also be
explained with the length of treatment (10 versus 20 days) being,
probably, the effect of dasatinib alone evident only after a longer
incubation period.
Adipogenic commitment of MSCs can be obtained in vitro by the
addition of a medium containing dexamethasone (1 mM), insulin
and 3-isobutyl-1-methylxanthine (a cAMP phosphodiesterase
inhibitor). However, dexamethasone alone at 100 nM does not
induce adipogenic differentiation (not shown).
Dasatinib is a powerful inhibitor of several Src and Src-like
kinases, and, thus it can affect a plethora of cellular events and
protein-protein interactions, including transduction pathways
correlated to cell lineage. In order to investigate potential
molecular mechanisms involved in MSCs adipogenesis and
affected by dasatinib, we pointed our attention on the MAPK
transduction pathway. As a matter of a fact, several studies
demonstrated that inhibition of Erk1/2 activity might influence
MSCs differentiation. Particularly, it has been reported that
OM induces the activation of Erk1/2 kinases during the process
of MSCs osteoblastic differentiation while the adipogenic
medium reduces remarkably Erk1/2 phosphorylation. Litera-
ture data also demonstrated that MSCs treatment with
inhibitors of MAPK pathway induces adipogenesis. Therefore,
the inhibition of Erk1/2 phosphorylation might be an
interesting molecular mechanism responsible for the dasatinib-
dependent MSCs adipogenesis. As reported in Figure 6D,
dasatinib clearly inhibits Erk1/2 activity at 7 and 9 days of
treatment and strongly reduces, at 11 days, its activation by
OM, thus suggesting that this dasatinib effect on MAPK
inhibition might have a role in the commitment of MSCs
towards adipogenesis.
The effect of dexamethasone might be also taken into
consideration. Indeed, our experiments demonstrate that the
molecule by itself might up-regulate PPARc expression, although
at a level not sufficient to cause morphological differentiation. On
Figure 3. Characterization of dasatinib-dependent MSCs
adipogenesis. Panel a) MSCs were treated as in Figure 1. At the
end of experiments the image of dasatinib-treated cells was captured
(A) and, then, the cells were stained with the Sudan Red staining
method (B). Panels b–d) MSCs were seeded at a density of 10
4 cells/
cm
2. After one day, 25 nM dasatinib was added plus b-glycerophos-
phate (Das/b-GP, Panel c) or plus 100 nM dexamethasone (Das/Dex,
Panel d). Control cells were shown in Panel b. Finally, after additional
3 weeks, the images were captured. The panels are representative of 4
independent experiments.
doi:10.1371/journal.pone.0028555.g003
Figure 4. Effect of dasatinib on PPARc expression in MSCs.
Panel a) MSCs were seeded at a density of 10
4 cells/cm
2. After one day,
25 nM dasatinib (Das) were added. After one week, 100 nM
dexamethasone (Dex) was added in some samples as reported in the
panel. After further 30 days, total RNA was prepared and the content of
PPARc transcript evaluated by semiquantitative RT-PCR. MW, molecular
weight standards. Glyceraldheyde 3-phosphate dehydrogenase
(GAPDH) was used as internal standard. Further details of RT-PCR are
reported under Materials and Methods Section. Panel b)T h e
experiment is similar to that in Panel 4a except that the content of
PPARc transcript was determined by quantitative RT-PCR. Further
details on this analysis are reported under Materials and Methods
Section. The results are expressed as percentage of control. The panels
are representative of 5 independent experiments.
doi:10.1371/journal.pone.0028555.g004
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adipogenic medium, suggesting its importance in the adipocytic
commitment. It is probable that the dasatinib-associated inhibition
of Erk1/2 activity might induce a partial increase of PPARc
strongly potentiated by dexamethsone.
During the development of this project, studies describing the
effect of dasatinib on human MSCs osteogenesis (but not its
adipogenic activity) have been published [56–58]. However, the
reported findings significantly disagreed [56–58]. Jonsson and
colleagues showed that dasatinib inhibits the proliferation of MSC
and their bone morphogenetic protein-dependent osteoblastic
differentiation [56]. This inhibition was demonstrated by reduc-
tion of AP activity, diminished calcification and reduced levels of
Runx2 and Osterix transcripts (two markers of osteoblastic
differentiation) [56]. The effect was evidenced at dasatinib
therapeutic concentrations (5–80 nM) [56].
Conversely, two studies suggested that dasatinib accelerates the
MSCs osteoblastic differentiation [57,58]. In one report, a
significant increase of AP activity and calcium deposition was
observed in MSCs when the molecule was added in association
with b-glycerophosphate after, respectively, 7 and 14 days [57]. In
the other investigation, MSCs were induced to differentiate in
osteoblastic cells by treatment with OM with or without dasatinib
[58]. The authors also found that the addition of dasatinib induced
Figure 5. Effect of dasatinib or bosutinib with or without dexamethasone on the expression of PPARc, CEBPa, LPL and SREBP1c in
MSCs. Panel a) MSCs were seeded at a density of 10
4 cells/cm
2. After one day, the cells were treated with: 100 nM dexamethasone (Dex); 25 nM
dasatinib/100nM dexamethasone (Das/Dex); 100 nM bosutinib/100nM dexamethasone (Bos/Dex); 1 mM dexamethasone (Dex); 25 nM dasatinib alone
(Das). After 10 days, total RNA was prepared and the content of PPARc, CEBPa, LPL and SREBP1c was evaluated by semiquantitative RT-PCR. MW,
molecular weight standards. Glyceraldheyde 3-phosphate dehydrogenase (GAPDH) was used as internal standard. Furthermore, in the analysis of
SREBP1c transcript, a K562 erythroid cell total RNA was employed, since it has been reported that these cells are rich of SREBP1c transcript. Additional
details of RT-PCR are reported under Materials and Methods Section. Panel b) MSCs were seeded at a density of 10
4 cells/cm
2. After one day, the cells
were treated respectively with: 25 nM dasatinib/100nM dexamethasone (Das/Dex); 25 nM dasatinib alone (Das), and 100 nM bosutinib (Bos) alone.
After 20 days, total RNA was prepared and the content of PPARc, CEBPa and LPL was evaluated by semiquantitative RT-PCR. MW, molecular weight
standards. Glyceraldheyde 3-phosphate dehydrogenase (GAPDH) was used as internal standard. In this experiment, we have increased the number of
PCR cycles from 30 to 35 in order to identify the occurrence of low amount of transcript. Additional details of RT-PCR are reported under Materials
and Methods Section. The panels are representative of 5 independent experiments.
doi:10.1371/journal.pone.0028555.g005
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mineralization, as compared with cultures grown in standard
medium or OM only [58].
Our study confirms that MCSs treatment with dasatinib
prevents osteogenesis [56]. We have also observed, according to
Jonsson and colleagues [56] and to experiments on imatinib [59]
that BCR-ABL inhibitors reduce MSCs proliferation (data not
showed). However, the major novelty of our investigation is the
observation, described for the first time, that dasatinib induces
adipogenic differentiation at a concentration similar to that
occurring in vivo. Moreover, the inhibition of Erk1/2 activity, a
well known effect of Src inhibitors, might direct (at least in part)
MSCs towards adipogenesis, in accordance with several previous
investigations [40,41]. Finally, it is reasonable that the inhibition of
osteoblastic differentiation by dasatinib might drive the cells
towards the adipogenesis, particularly in the presence of
dexamethasone.
The adipogenic effect of dasatinib on human MSCs is of
peculiar clinical interest. Indeed, the molecule represents a pivotal
drug in the treatment of CML. Since this neoplasia must be
considered a chronic disease, changes of the mesenchymal
component of bone marrow (after a prolonged therapy) might
represent an important potential side event that can affect both
bone turnover and hematopoiesis. The observation might have
even more relevance in view of the proposed use of the Src
inhibitor in the therapy of several solid cancers. Finally, our
findings suggest that strong caution must be taken in considering,
among the already clinically identified dasatinib side effects, the
possibility that it can cause a pathological adipogenesis of bone
marrow mesenchymal component.
Supporting Information
Figure S1 Immunophenotype of mesenchymal stem
cells from human bone marrow. MSC cells were prepared
as reported in Materials and Methods. MSCs from passage 2 were
harvested and labeled with antibodies against CD105 and CD29
(positive MSCs markers) and CD45, CD34 and CD14 (MSCs
Figure 6. Effect of TKIs with (or without) dexamethasone on the content of PPARc and p27
Kip1 proteins in MSCs and primary human
fibroblasts. The experiment was performed essentially as reported in Figure 5. Panel a) In this case, MSCs total cell extracts were prepared and
investigated by immunoblotting for the content of PPARc and p27
Kip1 (p27) protein. Actin was used for confirming the equal loading. Two different
film expositions (1 and 5 minutes) were performed to obtain a better evaluation of PPARc protein content. Additional details are reported under
Materials and Methods Section. Panel b) MSCs were seeded at a density of 10
4 cells/cm
2. After one day, MSCs were treated with 25 nM dasatinib
(Das) or cultured in adipogenic or osteogenic media. Subsequently, MSCs were cultured for 25 days and then collected. Finally, cell extracts were
prepared and investigated by immunoblotting for the content of PPARc and p27
Kip1 (p27) protein. Panel c) MSCs and human primary skin fibroblasts
were seeded at a density of 10
4 cells/cm
2. After 24 hours, 25 nM dasatinib (Das) or 100 nM bosutinib (Bos) were added to the cells, After 40 days, the
cells were collected and nuclear and cytosolic fractions prepared by Ne-Per as reported in Materials and Methods. The purity of nuclear and cytosolic
compartments was evaluated by immunoblotting with anti-HDAC1 (a nuclear protein) and anti-cofillin (a cytolic protein) antibodies. The results
confirmed the purity of fractions (data not reported). Finally, the content of PPARc and p27
Kip1 (p27) proteins was determined by immunoblotting.
Panels d and e) MSCs were seeded at a density of of 10
4 cells/cm
2. After one day, the medium was removed and substituted with osteogenic
medium or osteogenic medium plus dasatinib. At the reported days, MSCs were recovered and employed to evaluate (Panel d) phosphoErk1/2 and
Erk1/2 levels, or (Panel e) the level of phospho-tyrosine protein levels (pY). The panels are representative of 3 independent experiments.
doi:10.1371/journal.pone.0028555.g006
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the staining of cells with the indicated antibody.
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